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The prevalence of heart disease, especially heart failure, continues to increase, and cardiovascular disease
remains the leading cause of death worldwide. As cardiomyocytes are essentially irreplaceable, protein qual-
ity control is pivotal to cellular homeostasis and, ultimately, cardiac performance. Three evolutionarily
conserved mechanisms—autophagy, the unfolded protein response, and the ubiquitin-proteasome sys-
tem—act in concert to degrade misfolded proteins and eliminate defective organelles. Recent advances
have revealed that these mechanisms are intimately associated with cellular metabolism. Going forward,
comprehensive understanding of the role of protein quality control mechanisms in cardiac pathology will
require integration of metabolic pathways and metabolic control.Age-adjusted mortality from cardiovascular disease (CVD) has
decreased an astonishing 75% over the past 40 years (Nabel
and Braunwald, 2012). Many patients whowould have died previ-
ously now survive with an injured heart, predisposing them to the
clinical syndrome of heart failure. Life-saving successes such as
these, coupled with deterioration in lifestyle-related issues and
the epidemic of obesity, have culminated in dramatic increases
in the prevalence of heart failure. CVD accounted for 30% of all
deaths in 2008, and this is projected to rise to 35% in 2030 (Math-
ers and Loncar, 2006). By 2030,more than 40%of the USpopula-
tion is projected to suffer from some form of CVD, with estimated
direct and indirect costs exceeding $1 trillion (Mozaffarian et al.,
2014). Clearly, the spectrum of CVD continues to evolve, posing
ever-newchallenges to decipheringmechanismsof pathogenesis
in hopes of discovering new life-preserving therapies.
Protein Quality Control in Heart Disease
Protein quality control is vital to cellular homeostasis and integ-
rity. Loss of protein homeostasis leads to accumulation of mis-
folded proteins and protein aggregates with consequent proteo-
toxicity. Intricate adaptive responses have evolved to clear
aberrantly folded proteins and defective organelles. Multiple,
interdependent mechanisms are orchestrated to ensure protein
homeostasis and to respond to stress.
Loss or imbalance of protein quality control has been impli-
cated in numerous diseases, including neurodegenerative dis-
ease, CVD, diabetes, and cancer. As a post-mitotic cell, cardio-
myocytes possess little, if any, replicative capacity in adult life
(Bergmann et al., 2009). Thus, maintaining balanced protein
quality is fundamental to minimize cellular dysfunction and death
(Willis and Patterson, 2013). At the same time, it has been firmly
established that metabolic derangements contribute to the path-
ogenesis of heart disease (Lopaschuk et al., 2010). While protein
quality control is essential to maintain protein homeostasis,
recent studies have revealed that these mechanisms are also
actively engaged in the regulation of cardiac metabolism
(Figure 1). Here, we provide an overview of protein quality controlin heart under various stresses, placing emphasis on the inter-
play with metabolism.
Cellular Mechanisms of Protein Homeostasis
Protein homeostasis involves gene transcription, mRNA transla-
tion, protein post-translational modification, high-order complex
assembly, and protein clearance, all of which participate in every
aspect of cardiac physiology and pathology. While considerable
progress has emerged in our understanding of the regulation of
gene expression in the heart, advances in elucidating protein
quality control are relatively limited.
Multiple cellular mechanisms serve as surveillance and moni-
toring systems to ensure protein homeostasis in the cardiomyo-
cyte (Mearini et al., 2008; Wang and Robbins, 2014). Autophagy
and the ubiquitin-proteasome system (UPS) are the most impor-
tant proteolytic cascades to eliminate misfolded proteins and
defective organelles. These mechanisms involve the lysosome
and proteasome, respectively. The unfolded protein response
(UPR) is an adaptive process to accommodate protein-folding
stress in the endoplasmic reticulum (ER) (Hetz et al., 2013;Walter
and Ron, 2011).
A characteristic feature of each of these three processes is
inherent dichotomy: each is capable of beneficial changes, and
each is capable of destructive, even lethal, harm.Whether the di-
chotomy intrinsic to those processes stems from quantitative
differences (too much or too little), as opposed to qualitative dis-
tinctions, remains an ongoing puzzle. Either way, defects in each
of these regulatory mechanisms have been reported in heart
disease, and modulation of their activities holds promise in
combating disease.
Autophagy, a Self-Eating Process
Autophagy is an evolutionarily conserved process in which a cell
cannibalizes small portions of its cytoplasm (Mizushima et al.,
2008). At least three forms of autophagy have been described,
all of which involve delivery of cargo to the lysosome for degra-
dation. Among them, macroautophagy (herein referred to asCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 215
Figure 1. Protein Quality Control and
Cardiac Metabolism in Heart Disease
Disease-related stress on the myocardium trig-
gers increased demand for protein folding and
protein damage. These events, in turn, activate the
UPR, autophagy, and the UPS. Glucose and FFA
are the major nutrients supporting energy pro-
duction in the myocardium. Recent insights have
uncovered complex interplay between these two
major cellular processes, including bidirectional
signaling, transcriptional control, and substrate
provision.
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functional implications in virtually every cell type.
Autophagy is a regulated, highly dynamic process, governed
by more than 30 autophagy-related proteins (ATGs) (Figure 2)
(Feng et al., 2014). Initiation of autophagy is triggered by nutrient
deprivation or lack of growth factor support. Mammalian target
of rapamycin (mTOR), the master regulator of cell growth, is
associated with the ULK1-ATG13-FIP200 protein complex, in-
hibiting it by phosphorylation. Starvation leads to inactivation
and dissociation of mTOR from ULK1. Liberated ULK1, in turn,
is activated to phosphorylate and recruit a class III PI3K complex
to the site of formation of an isolation membrane, the nascent
organelle for cargo engulfment. The class III PI3K complex con-
sists of VPS34, Beclin 1, VPS15, and ATG14L, and its primary
function is to generate PI3P and attract more ATGs to the nucle-
ation site.
Two ubiquitin-like conjugation systems, working in parallel,
then participate in vesicle expansion and elongation. In the first
one, ATG12 is activated by an E1-like enzyme, ATG7, transferred
to an E2-like enzyme, ATG10, and finally to ATG5. After interact-
ing with ATG16L, the ATG12-ATG5-ATG16L complex functions
similarly to an E3 ligase. In the second conjugation system,
ATG8 is initially processed by ATG4, a cysteine protease, to
expose a C-terminal glycine. ATG8 is then activated by ATG7,
transferred to an E2-like molecule, ATG3, and finally conjugated
by the ATG12-ATG5-ATG16L complex to phosphatidylethanol-
amine (PE) to become ATG8-PE. The double-membrane vesicle
then engulfs portions of cytoplasm, generating a discrete struc-
ture termed an autophagosome. The autophagosome ultimately
delivers its cytosolic cargo to the lysosome, forming an autolyso-
some. Acid hydrolases within the lysosome digest macromole-
cules into amino acids, lipids, nucleotides, and carbohydrates,
along with the autolysosome inner membrane, to yield cellular
building blocks to refuel the cell.
Autophagy in Starvation
As a continuously working pump, the heart consumes robust
quantities of ATP, more than any other organ in the body. That
said, myocardial energy reserves in human myocardium are
remarkably low, sufficient for fewer than ten contractions (Stan-
ley et al., 2005). As a result, cardiomyocytes must generate en-216 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.ergy continuously, consuming nutrients
constantly and without interruption (Lo-
paschuk et al., 2010).
During mammalian fetal development,
nutrients are available continuously. Atbirth, however, nutrient supply is abruptly interrupted, and neo-
nates experience an energy crisis before nutrients are restored
in the form of mother’s milk. During this critical window, auto-
phagy is activated in numerous cell types; in mouse heart, auto-
phagy is activated within 30 min post-delivery and remains high
for at least 24 hr (Kuma et al., 2004). Genetic suppression of this
autophagic response dramatically reduces survival in nutrient-
deprived neonates as compared to wild-type controls.
Conversely, forced feeding of milk enhances survival in auto-
phagy-deficient neonates, highlighting the role of autophagy in
supplying energy at this stage. More recent studies demonstrate
that restoration of nutrient supply rapidly suppresses autophagy
through insulin signaling, thereby obviating excessive ‘‘self-
eating’’ and promoting normal development (Riehle et al., 2013).
Likewise, in adult mice exposed to starvation conditions, car-
diomyocyte autophagy plays a pivotal role to maintain cellular
homeostasis and sustain pump function. Indeed, autophagy is
significantly induced in heart by as little as 12 hr of nutrient depri-
vation (Kanamori et al., 2009). Normally, heart function is pre-
served over the course of 3 days of food deprivation. However,
when autophagy is inhibited by administration of Bafilomycin
A1, cardiac performance is impaired, coupled with significant
decreases in myocardial concentration of amino acids and
ATP. These in vivo findings are corroborated by in vitro observa-
tions. In cultured adult cardiomyocytes, nutrient deprivation trig-
gers necrotic cell death by day 4 (Maruyama et al., 2008). Inhibi-
tion of autophagy pharmacologically or by means of RNAi
knockdown of key ATGs accelerates cell death, while stimulation
of autophagy decelerates death. Similar findings have been re-
ported in neonatal rat ventricular myocytes (NRVMs) and HL-1
cells, pointing to a common protective role for autophagy in
the metabolic stress of starvation (Hariharan et al., 2010; Xu
et al., 2013).
Adult heart derives 50%–70% of its energy from oxidation of
free fatty acids (FFAs), while the rest comes from oxidation of
glucose, lactate, and other nutrients. Given its incessant require-
ment for energy, the myocardium is an obligate omnivore,
consuming any nutrient available to generate ATP.When nutrient
supplies are limiting, autophagy fuels the heart through several
routes (Rabinowitz and White, 2010). Nucleic acid degradation
yields ribose, which can feed into glycolysis through the pentose
Figure 2. The Autophagy Pathway
Autophagy is an evolutionarily conserved self-eating process. Autophagy is dynamic, involving multiple steps of initiation, vesicle nucleation, elongation/
expansion, and fusion. Engulfed cargo is digested by acid hydrolases from the lysosome, and degraded components are released into the cytosol to meet
energetic demand. Several complexes participate in autophagosome formation at various steps, including an initiation complex, the class III PI3K complex, and
two ubiquitin-like systems.
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digestion can be channeled into glucose and FFA oxidation
pathways, respectively. Proteins are initially broken down into
peptides and, ultimately, amino acids. Following deamination,
degradation products derived from various amino acids serve
as key intermediates supporting major metabolic pathways.
For example, glutamate and alanine can be converted into a-ke-
toglutarate and pyruvate, respectively, both of which feed
directly into the TCA cycle. Collectively, cardiac autophagy not
only ‘‘takes out the trash’’ but it also recycles that trash to sup-
port metabolism.
Autophagy as a Housekeeping Process
Autophagy is the primary means of degrading long-lived proteins
and defective organelles. In post-mitotic cells, such as cardiac
myocytes and neurons, which have very limited capacity for
regeneration, mechanical and oxidative stress over the course of
a lifetime must be repaired. Here, the housekeeping function of
autophagy is critical to sustain cellular viability and performance.
Deficiency of autophagy by genetic silencing of ATG5 under
basal conditions triggers cardiac hypertrophy and ventricular
dilatation, possibly due to toxic accumulation of defective organ-
elles (Nakai et al., 2007). This is a cell autonomous response, as
knockdown of ATG7 in NRVMs is sufficient to recapitulate these
phenotypes. Danon disease is a lysosomal glycogen storage
disease caused by mutation of LAMP2, a principal lysosome
membrane protein (Nishino et al., 2000). Loss of LAMP2 by tar-
geted silencing inmice leads to accumulation of autophagic vac-
uoles, extension of the half-life of long-lived proteins, and dete-
rioration of cardiac contractility, again highlighting the critical
role of autophagy in maintaining cardiomyocyte homeostasis
(Tanaka et al., 2000).The housekeeping role of autophagy is further exemplified in
its actions to antagonize cardiac proteotoxicity. In cardiomyo-
cytes, alpha-B crystallin (CryAB) is a molecular chaperone
serving to prevent aggregation of highly abundant proteins,
such as desmin. Expression of a dominant-negative mutant of
CryAB (CryABR120G) elicits protein aggregates, myofibril
disarray, and cardiomyopathy (Rajasekaran et al., 2007; Sanbe
et al., 2004). Our lab has shown that overexpression of this
mutant human CryAB in NRVMs is sufficient to trigger autophagy
(Tannous et al., 2008). Inhibition of autophagy by 3-MA leads to
increases in aggresome size and insolubility. Moreover, blunting
autophagy in vivo accelerates pathological remodeling in
CryABR120G-expressing heart and leads to heart failure (Tan-
nous et al., 2008). Consistently, boosting autophagy by overex-
pressing ATG7 reduces aggregate content and cytotoxicity both
in vivo and in vitro (Bhuiyan et al., 2013; Pattison et al., 2011).
Autophagy in Cardiac Hypertrophy
Hypertension affects one in three Americans (Mozaffarian et al.,
2014). In response to high blood pressure and consequent in-
creases in ventricular wall stress, the heart undergoes a transfor-
mation that involves hypertrophic growth and incorporation of
new sarcomeres in parallel. Held to be an acute, adaptive
response initially, cardiac hypertrophy, when persistent, is mal-
adaptive (Frey et al., 2004). In epidemiological studies, left ven-
tricular hypertrophy is an independent risk factor for systolic
dysfunction and heart failure, a clinical syndrome wherein the
hearts in unable to maintain adequate perfusion of peripheral or-
gans (Mozaffarian et al., 2014). Extensive efforts have been mar-
shaled to decipher mechanisms governing the transition from
hypertrophy to heart failure, which, however, remain elusive (Hei-
neke and Molkentin, 2006; Burchfield et al., 2013).Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 217
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of sarcomeres within cardiomyocytes. It involves profound
structural, electrophysiological, functional, and metabolic re-
modeling (Hill and Olson, 2008). Numerous reports demon-
strate that autophagy participates in this process. In early
phases of hypertrophic growth, autophagy may be acutely sup-
pressed to favor anabolism and rapid cardiomyocyte growth.
Indeed, early studies reported that short-term (10 min) infusion
of isoproterenol, a b-adrenergic agonist that elicits cardiac hy-
pertrophy, in rat heart leads to a decrease of autophagic vacu-
oles (Pfeifer et al., 1987). Thoracic aortic constriction (TAC) is a
well-established procedure in rodent models wherein the aortic
arch is constricted surgically to increase afterload. TAC in mice
has been suggested to lead to suppression of autophagy
1 week after surgery (Nakai et al., 2007). However, steady-state
levels of LC3-II and p62 were emphasized in this study, which
may not provide a reliable evaluation of autophagic flux. Ulti-
mately, anabolism and catabolism achieve equipoise at higher
levels.
Using a mouse model of severe TAC (sTAC), we reported that
autophagy is induced as early as 24 hr after surgery, along with
augmentation of lysosomal markers (Zhu et al., 2007). Blunting
autophagy in a model of Beclin 1 haploinsufficiency (Beclin 1+/
mice) significantly reduced hypertrophic growth and cardiac re-
modeling, whereas cardiomyocyte-restricted overexpression of
Beclin 1 exacerbated hypertrophy and heart failure triggered
by pressure overload. Further, angiotensin II infusion for 4 weeks
in mice triggers significant hypertrophy and autophagy in heart
(Dai et al., 2011). And these in vivo findings have been confirmed
in vitro; angiotensin II treatment for 48 hr elicits increases in auto-
phagy in NRVMs (Porrello et al., 2009).
Intriguingly, pharmacological intervention to block autophagy
is sufficient to blunt hypertrophic growth. Chronic inhibition of
histone deacetylase (HDAC) activity by small molecules elicits
a reduction in autophagic activity. HDAC inhibition in mice effec-
tively suppresses TAC-induced hypertrophy (Antos et al., 2003;
Kong et al., 2006). Importantly, when treatment is initiated after
establishment of cardiac hypertrophy, suppression of autophagy
can reverse hypertrophic growth and restore systolic perfor-
mance (Cao et al., 2011). Together, these results highlight the
importance of autophagy in afterload-induced cardiac hypertro-
phic growth and point to a novel therapeutic strategy to tackle
maladaptive cardiac remodeling.
Some findings, however, are seemingly contradictory (Nakai
et al., 2007). These investigators engineered mice harboring car-
diomyocyte-specific deficiency of ATG5. When subjected to
TAC, ATG5 knockout heart manifested more profound hypertro-
phy, exacerbated pathological remodeling, and systolic
dysfunction. Whereas the reasons underlying these apparent
discrepancies remain unclear, we suggest that differences in
the models being employed contribute. Autophagy, like many
other biological processes, exists as a continuum (Rothermel
and Hill, 2008). Basal autophagy is essential to maintain cellular
homeostasis. Complete abrogation of autophagy in ATG5
knockout hearts likely predisposes cardiomyocytes to load-
induced stress. In that context, TAC triggers a severe maladap-
tive response. In Beclin 1+/ mice, however, where autophagic
flux is essentially halved, pressure overload induces autophagy
within an adaptive range, and cardiac performance is well pre-218 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.served. We suggest that increased levels of autophagic flux in
wild-type mice subjected to pressure stress are maladaptive.
When autophagic flux is amplified by Beclin 1 overexpression,
maladaptive remodeling is further increased. Thus, optimal
levels of autophagic flux are critical to maintain cellular homeo-
stasis and cardiac performance.
It is firmly established that cardiac hypertrophy is associated
with profound metabolic remodeling. The main source of ATP
production in healthy adult heart is FFA. During hypertrophic
growth, utilization of glucose increases, ultimately becoming
an important fuel source for ATP generation. Early studies
showed that ATP derived from glycolysis increases from 7% in
control to 19% in hypertrophied heart (Allard et al., 1994).
Concomitantly, ATP production from FFA decreases from 70%
to 55%. Increases in glycolysis are, however, uncoupled from
further oxidative phosphorylation, raising the prospect of ineffi-
cient energetics.
It is also possible that the increase in glycolysis, uncoupled
from oxidative phosphorylation, may provide critical metabolic
intermediates for hypertrophic growth. To achieve significant
enlargement of the cardiomyocyte, nutrients may not be
completely oxidized to ATP, CO2, and H2O. Rather, metabolites
from glycolysis may be channeled to biosynthesis of macromol-
ecules (Locasale and Cantley, 2011). Consistent with this notion,
intermediate metabolites, such as glucose-6-phosphate, fruc-
tose-6-phosphate, 3-phosphoglycerate, 2-phosphoglycerate,
and phosphoenoylpyruvate are all elevated in hypertrophied
heart of Dahl salt-sensitive rats (Kato et al., 2010). Likewise,
NADPH, a metabolite of the pentose phosphate pathway, is
significantly increased as well. However, this hypothesis of se-
lective diversion from downstream substrate oxidation to sup-
port growth remains to be conclusively verified.
Cardiac metabolism is further altered during the transition
from hypertrophy to heart failure (Lopaschuk et al., 2010).
Glucose uptake is enhanced yet more, while uncoupling from
oxidative phosphorylation persists. At the same time, FFA oxida-
tion is reduced. To maintain normal TCA flux, key intermediates
are replenished via anaplerosis from glycolytic pyruvate and up-
regulation of malic enzyme activity (Sorokina et al., 2007). These
metabolic alterations, however, bypass energy-yielding reac-
tions and contribute to reduced energetic efficiency in heart
failure.
Studies from the cancer field may shed light on mechanisms
whereby autophagy affects cardiomyocyte metabolism (Kenific
and Debnath, 2015; Rabinowitz and White, 2010). In oncogenic
H-Ras-transformed mouse embryonic fibroblasts, autophagy is
induced following extracellular matrix detachment. Inhibition of
autophagy by knockout of ATG5 leads to suppression of
anchorage-independent transformation, attenuation of prolifera-
tion, and inhibition of glycolysis (Lock et al., 2011). Similar find-
ings have been reported in mammary tumor cells silenced for
FIP200 (Wei et al., 2011). Although the specific target(s) of auto-
phagy within the glycolytic pathway remain to be uncovered,
these results highlight the intrinsic connections between auto-
phagy and glycolysis.
Excessive activation of autophagy accelerates the decompen-
sation process and promotes heart failure. Over-activation of
autophagy may non-selectively degrade essential metabolic
enzymes and mitochondria, exacerbating metabolic
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robust increases in autophagy in heart, and attenuation of auto-
phagy can decelerate cardiac remodeling (Zhu et al., 2007).
Chaanine et al. (2012) reported excessive autophagic elimination
of mitochondria in heart failure triggered by pressure overload.
Inhibition of autophagy by 3-MA led to improvements in contrac-
tility and blunting of pathological remodeling (Chaanine et al.,
2012). Collectively, we suggest that autophagy in the initial
phase of hypertrophic transformation is adaptive by modulating
cardiac metabolism though induction of glycolysis. Excessive
autophagy, however, promotes maladaptive remodeling and ac-
celerates disease progression.
Autophagy in Ischemic Heart Disease
Limitations in the delivery of oxygen and nutrients to the myocar-
dium are common, typically resulting from atherosclerotic nar-
rowing of coronary arteries. Complete occlusion of a coronary
artery ignites a process culminating in irreversible cell death. In
most instances of ischemic disease, blood supply is restored,
spontaneously or therapeutically. Whereas cell death is rescued
by the restoration of blood flow, a second wave of toxic events
accompanies this response, termed reperfusion injury (Hausen-
loy and Yellon, 2013; Turer and Hill, 2010).
The hypoxic/anoxic environment of ischemia is akin to starva-
tion and triggers potent induction of autophagy. Studies in the
late 1970s demonstrated that autophagic vacuoles are strongly
induced in rabbit heart after only 40 min of hypoxia (Decker
and Wildenthal, 1980). In a swine model of ischemic cardiomy-
opathy, widespread upregulation of autophagic markers,
including LC3-II (ATG8), Beclin 1, and cathepsins, are seen
(Yan et al., 2005). More recently, Sadoshima and colleagues re-
ported significant autophagy induction in rodent heart from only
30 min of ischemia (Matsui et al., 2007).
It is widely agreed that autophagy elicited by myocardial
infarction protects the heart from ischemic injury. Due to abrupt
interruption of exogenous nutrient supply, metabolites from au-
tophagic digestion become a major source for energy produc-
tion. Moreover, autophagy-stimulated glycolysis may be an
adaptive feature during hypoxia, as glycolysis can generate
ATP in the absence of oxygen. Some evidence suggests that
peak autophagy induction in ischemia is coincident with sup-
pression of apoptosis, highlighting a cardioprotective role (Yan
et al., 2005). Stimulation of autophagy in mice using TAT-p27 re-
duces infarct size and improves cardiac performance after
myocardial infarction (Sun et al., 2014). Moreover, autophagy
may be protective by eliminating defective mitochondria,
thereby limiting accumulation of toxic reactive oxygen species
(ROS) (Zhang et al., 2008).
Timely and effective reperfusion of ischemic myocardium is
the most effective means of mitigating cardiac damage. Again,
in the late 1970s, it was shown that reperfusion after hypoxia in
rabbit heart elicits a second wave of autophagy (Decker and
Wildenthal, 1980). Similar findings have been reported in mouse
heart (Matsui et al., 2007), HL-1 cells (Hamacher-Brady et al.,
2006), and NRVMs (Sengupta et al., 2011). Although induction
of autophagy by ischemia/reperfusion (I/R) is firmly established,
its functional role is likely complex and time dependent. In the
setting of suppressed autophagic activation due to Beclin 1
haploinsufficiency, I/R injury is attenuated (Matsui et al., 2007).Likewise, suppression of autophagy in vitro using 3-MA in-
creases cell viability after I/R (Valentim et al., 2006). Together,
these results points to a detrimental role of autophagy in I/R.
In contrast, there is evidence that enhanced autophagy pro-
tects cardiomyocytes from I/R damage (Hamacher-Brady
et al., 2006). Stimulation of autophagy by chloramphenicol suc-
cinate in pigs is cardioprotective against I/R (Sala-Mercado
et al., 2010). Further, elevated basal levels of autophagy in
high-altitude residents is associated with diminished I/R injury
(Hu et al., 2014). In aggregate, these findings point to a beneficial
role of autophagy in I/R.
This apparent discrepancy may be reconciled by understand-
ing the dynamic nature of autophagy. A static snapshot of LC3-II
levels does not provide an accurate picture of autophagic flux,
because either an increase in autophagy initiation (increased au-
tophagic flux) or blockageof downstreamprocessing (decreased
autophagic flux) generate the same result. Some evidence of
impaired autophagic flux was reported in HL-1 cells exposed to
I/R (Hamacher-Brady et al., 2006). Working with both murine
and rabbit models of I/R injury, we have reported that autophagic
flux is suppressed in heart, and stimulating flux is cardioprotec-
tive (Xie et al., 2014). The blockage of downstream processing
is likely due to decreases in the key lysosomal protein LAMP-2
(Ma et al., 2012). Beclin 1 haploinsufficient mice may manifest
less cardiac injury from I/R due to attenuated accumulation of un-
processed autophagosomes (Matsui et al., 2007). In aggregate,
modulation of autophagic flux, with effects on both protein
quality control and metabolism, represents a promising means
to ameliorate I/R injury to the myocardium.
UPR
Up to 35% proteins require concerted processing by translation,
folding, assembly, and secretion in the ER (Blobel, 2000). When
these secretory or transmembrane molecules are not processed
properly, accumulating in the ER, an evolutionarily conserved
process is activated, termed the UPR (Walter and Ron, 2011).
The UPR serves to relieve ER stress by diminishing the transla-
tion of newprotein, promoting expression of protein chaperones,
and degrading excess protein through ER-associated degrada-
tion (ERAD) and via autophagy. Further, cytosolic chaperones
andmitochondrial chaperones play important roles in cardiopro-
tection in the settings of several heart diseases (Tarone and
Brancaccio, 2014; Willis and Patterson, 2010).
There are three arms of the UPR that transmit signals to the nu-
cleus to elicit downstream events (Figure 3). PKR-like ER kinase
(PERK) is a transmembrane protein kinase in the ER. In the basal
state, PERK is sequestered in an inactive state by interacting
with BiP, an ER-resident chaperone. In the setting of increased
demand for protein folding, BiP preferentially binds hydrophobic
domains of folding proteins, liberating PERK to oligomerize and
autophosphorylate. Active PERK phosphorylates eIF2a, a trans-
lational initiation factor, suppressing its activity and effectively
reducing global mRNA translation to create a ‘‘time window for
repair’’ in the ER. Phosphorylated eIF2a, however, can selec-
tively promote translation of certain mRNAs harboring a small
open reading frame in the 50-UTR, including ATF4. ATF4 medi-
ates expression of ER chaperones to facilitate protein folding.
Inositol-requiring 1 (IRE1) is the most highly conserved branch
of the UPR, present from yeast to mammals. IRE1, uponCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 219
Figure 3. The UPR
The UPR is an adaptivemechanism to copewith protein folding stress in the ER.Misfolded proteins in the ER occupy the ER-resident chaperone BiP. Three signal
transducers of the UPR are induced by a variety of mechanisms to attenuate global protein translation and stimulate expression of genes coding for proteins
involved in protein chaperoning, autophagy, ER-associated protein degradation, and metabolic regulation. In the setting of unremitting stress, cell death ensues
to eliminate terminally defective cells. nATF6, nuclear ATF6.
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ibonuclease activity. One prominent target of IRE1 is X-box bind-
ing protein 1 (Xbp1). Cleavage of a cryptic 26 bp intron creates a
frame shift, and the resultant spliced Xbp1 (Xbp1s) is a potent
transcriptional activator, driving expression of genes coding for
multiple chaperones and elements of ERAD.
In contrast to PERK and IRE1, the third element of the UPR,
activating transcription factor 6 (ATF6), is translocated from the
ER to Golgi when its binding partner within the ER is occupied
by protein clients. Then, ATF6 is cleaved by two proteases,
and the cytoplasmic domain of ATF6 is released and transported
to the nucleus where it stimulates transcription of genes coding
for ER-resident chaperones (Ye et al., 2000).
As noted, activation of the UPR attenuates global protein
translation, promotes gene expression of ER chaperones, and
enhances ERAD to degrade terminally misfolded proteins. If all
these adaptive attempts fail in the face of persistent stress,
apoptosis ensues for the benefit of whole organism (Tabas and
Ron, 2011). Recent studies indicate the three branches also
exert partially overlapping but distinct functions in the determi-
nation of cell fate (Lin et al., 2007). Given the widespread and
diverse events triggered by the UPR, it is not surprising that per-
turbations of the UPR have been implicated in the pathogenesis
of multiple diseases, including cancer (Wang and Kaufman,
2014), CVD (Doroudgar and Glembotski, 2013), neurodegenera-
tive disease (Hetz and Mollereau, 2014), and diabetes (Back and
Kaufman, 2012; Fu et al., 2012).
UPR in Cardiac Hypertrophy
Cardiac hypertrophic growth requires biosynthesis of numerous
proteins and lipids. As a consequence, the protein folding load
within the ER is high. Surprisingly, there are relatively few studies
of UPR induction in load-induced heart growth. Early work re-220 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.ported that markers of the UPR are strongly induced at 1 and
4 weeks after TAC in mice, which is accompanied by increases
in apoptosis and deterioration of contractility (Okada et al.,
2004). This group went further to present evidence that CHOP,
a downstream pro-apoptotic target of the UPR, is responsible
for the detrimental effects of the UPR during pressure overload.
Accordingly, deletion of CHOP is associated with blunting of car-
diac hypertrophy and improvements in cardiac performance (Fu
et al., 2010). Whereas the specific UPR branches responsible for
these events were not elucidated, PERK is likely involved based
on stimulation of eIF2a phosphorylation and CHOP induction.
Other work, however, found that ATF6 activation suppresses hy-
pertrophic growth in vitro by directly targeting RCAN1 (Belmont
et al., 2008).
Cardiac hypertrophy also entails profound shifts in glucose uti-
lization and FFA oxidation. Cardiac insulin signaling is crucial for
load-induced hypertrophic growth, as reductions in plasma insu-
lin suppress cardiac enlargement and systolic dysfunction (Shi-
mizu et al., 2010). This finding is reminiscent of the action of
Xbp1s to sensitize hepatocytes to the action of insulin (Deng
et al., 2013). Further, Taegtmeyer and colleagues have reported
that glucose flux through the hexosamine biosynthetic pathway
(HBP) is enhanced in cardiac hypertrophy (Young et al., 2007).
We recently showed that Xbp1s is the upstream transcription
factor that directly activates expression of multiple enzymes of
hexosamine biosynthesis, and Xbp1s overexpression in heart
leads to elevations of UDP-N-acetylglucosamine (Wang et al.,
2014). However, the precise role of Xbp1s in cardiac hypertrophy
remains elusive.
UPR in I/R Injury
In contrast to the dearth of studies of the UPR in cardiac hyper-
trophy, numerous reports have demonstrated strong induction
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is induced 3-fold in the viable peri-infarct region of human
myocardium (Severino et al., 2007). Likewise, we and others
have found that Xbp1s is upregulated in human heart failure of
ischemic etiology, suggesting that the UPR is an intrinsic
component of the cardiac stress response (Sawada et al.,
2010; Wang et al., 2014). Coronary occlusion in pigs induces
all three branches of the UPR (Xin et al., 2011). Consistently, acti-
vation of ER stress has been observed in rodent models of
myocardial infarction. Glembotski and colleagues showed that
BiP levels are increased in the infarct zone after permanent cor-
onary ligation in mice (Thuerauf et al., 2006). Using NRVMs, the
same group reported potent induction of BiP, Xbp1s, and
CHOP by hypoxia. A dominant negativemutant of ATF6 inhibited
BiP promoter activation by hypoxia (Doroudgar et al., 2009).
Further, knockdown of ATF6 by siRNA leads to blunting of hyp-
oxia-induced BiP induction, contributing to NRVM cell death. In
contrast, activation of the PERK pathway by hypoxia has not
been widely reported in NRVMs. However, PERK activation
and downstream eIF2a phosphorylation in hypoxia have been
reported in human carcinoma cells and fibroblasts. The conse-
quent inhibition of protein translation is required for cell survival
(Koumenis et al., 2002). PERK deficiency or expression of a
dominant-negative mutant of PERK leads to reduction of eIF2a
phosphorylation and diminished cell viability, while forced acti-
vation of PERK promotes survival in hypoxia (Lu et al., 2004).
Collectively, these results point to robust induction of the UPR
by I/R in heart, a response which contributes to the maintenance
of cellular homeostasis and cardiomyocyte survival.
Mechanistically, the cardioprotective effects of the UPR have
been attributed largely to induction of ER chaperones and
consequent enhanced protein folding. Indeed, overexpression
of wild-type, but not mutant, PDI protects HL-1 cells from
apoptosis under hypoxia conditions (Severino et al., 2007).
Moreover, adenoviral-mediated expression of PDI in vivo is
strongly cardioprotective in acute myocardial infarction, with
improvements in contractility and reductions in infarct size. Hyp-
oxia provokes elevations of ROS and deterioration of oxidative
protein folding in the ER. Overexpression of chaperones en-
hances ER folding capacity, prevents accumulation of misfolded
proteins, and improves survival.
Additionally, hypoxia is accompanied by impairment of oxida-
tive phosphorylation, reduction in nutrient supply due to defi-
ciency of growth factor signaling, and defects in energetics. In
this state, enhancements in insulin signaling, glucose uptake,
and glycolysis provide significant survival advantage. In fact,
recent studies have delineated a significant metabolic role of
the UPR, especially the Xbp1s pathway (Back and Kaufman,
2012). Thus, the relative contributions to UPR-mediated cardio-
protection of promoting the ER folding environment by chap-
erone induction versus metabolic improvements by Xbp1s
remain to be determined.
Ample evidence shows that reperfusion after ischemic insult
(I/R) triggers strong UPR activation in heart. Extensive efforts
have been directed at dissecting pathological mechanisms of
I/R injury, with calcium mishandling, over-production of ROS,
metabolic derangements, and inflammation as widely cited cul-
prits (Hausenloy and Yellon, 2013; Murphy and Steenbergen,
2008; Turer and Hill, 2010). Intriguingly, these alterations arewell established triggers of the UPR (Schro¨der and Kaufman,
2005). Reperfusion of mouse heart after 50min of ischemia leads
to potent induction of Xbp1s, BiP, and eIF2a phosphorylation in a
time-dependent manner (Miyazaki et al., 2011). Similarly, elicita-
tion of the UPR in heart in vivo occurs early (Wang et al., 2014).
Splicing of Xbp1 occurs as early as 5 min into the reperfusion
phase of I/R in mouse. These findings have been corroborated
in vitro with NRVMs, highlighting a cardiomyocyte-autonomous
phenomenon (Thuerauf et al., 2006; Wang et al., 2014).
Functionally, upregulation of the UPR confers strong cardio-
protective effects. Das and colleagues reported a significant
beneficial effect of brief exposure to tunicamycin or thapsigargin
to elicit ER stress in rat (Petrovski et al., 2011). Likewise, multiple
studies from the Glembotski group suggest that induction of
ATF6 is cardioprotective. In a tamoxifen-inducible system, cardi-
omyocyte-specific overexpression of active ATF6 triggers signif-
icant protection against I/R damage ex vivo and in vivo (Martin-
dale et al., 2006), a finding consistent with improvements in
survival in vitro by simulated I/R (sI/R) (Doroudgar et al., 2009).
We have reported that overexpression of Xbp1s in cardiomyo-
cytes blunts I/R injury and improves cardiac performance in
mice (Wang et al., 2014). Conversely, cardiomyocyte-specific
knockout of Xbp1 amplifies I/R damage and exacerbates deteri-
oration in cardiac function. Importantly, further work using Xbp1s
gain- and loss-of-function strategies in vitro yielded consistent
results, suggesting that Xbp1s is necessary and sufficient to
protect cardiomyocytes from I/R insult. In addition, activation
of the pro-apoptotic branch of the UPR contributes to cardiac
injury, as highlighted by improvements in cardiac function in
CHOP-deficient animals (Miyazaki et al., 2011). In aggregate,
the UPR is acutely induced by I/R in heart, which helps to restore
cellular homeostasis and accelerate functional recovery from re-
perfusion.
UPR and the HBP
The intimate association between the UPR and carbohydrate
metabolism prompted us to investigate the potential role of the
UPR in regulating glucose utilization. Up to 5% of glucose is
metabolized via the HBP. Under certain conditions, the contribu-
tion may be significantly greater (Zachara, 2012). Glucose is
initially phosphorylated to glucose-6-phosphate and then con-
verted to fructose-6-phosphate. Glutamine fructose-6-phos-
phate aminotransferase (GFAT), the rate-limiting enzyme of the
HBP, converts fructose-6-phosphate to glucosamine-6-phos-
phate. After that, an acetyl group is conjugated by glucos-
amine-phosphate N-acetyltransferase (GNPNAT), and N-acetyl-
glucosamine-6-phosphate is formed, which is then converted to
N-acetylglucosamine-1-phosphate by phosphoglucomutase 3
(PGM3). After activation, UDP-GlcNAc is generated, which is
an important donor for biosynthesis of glycans, proteoglycans,
glycolipids, and O-GlcNAc modifications.
Protein O-GlcNAc modification (O-GlcNAcylation) is a promi-
nent post-translational modification of thousands of cytosolic
and nuclear proteins. This event governs protein subcellular
localization, protein-protein interactions, enzymatic activity,
and protein function (Bond and Hanover, 2013; Hart et al.,
2011). The O-GlcNAcylation reaction is catalyzed by O-GlcNAc
transferase (OGT) and antagonized by O-GlcNAcase (OGA).
UDP-GlcNAc, a cellular sugar derivative, is the donor moleculeCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 221
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shown that the enzymatic activity of OGT is largely driven by the
concentration of the UDP-GlcNAc substrate, the end-product of
the HBP.
Although chronic activation of the HBP and protein O-GlcNA-
cylation may be pathological, early studies firmly established
that acute stimulation of O-GlcNAcylation in the heart is strongly
cardioprotective under various stress conditions including I/R
(Bond and Hanover, 2013; Marsh et al., 2014). Cardiomyocyte-
specific deletion of OGT, and consequent suppression of
O-GlcNAcylation, leads to deteriorations in the response to
myocardial infarction, with increased fibrosis, apoptosis, and
pathological remodeling (Watson et al., 2010). Importantly, ele-
vations in O-GlcNAc in heart are associated with ischemic pre-
conditioning, a classical cardioprotective maneuver (Jones
et al., 2008). Pharmacological increases in O-GlcNAc in cardiac
myocytes improve cell survival in hydrogen peroxide treatment,
which is potentially linked tomaintenance ofmitochondrial integ-
rity. Further, overexpression of OGT and consequent elevation of
O-GlcNAcylation protects NRVMs from sI/R damage (Champat-
tanachai et al., 2008). Conversely, knockdown of OGT leads to
decreased cell survival. Moreover, pharmacological treatment
(PUGNAc) to inhibit OGA and thereby increase O-GlcNAcylation
confers strong protection against I/R damage ex vivo (Liu et al.,
2007). Collectively, these data suggest that acute increases in
protein O-GlcNAc modification in cardiomyocytes are cardio-
protective, possibly mediated by inhibition of apoptosis and
enhanced mitochondrial function.
At least two questions remain regarding O-GlcNAcylation and
cardioprotection. What stimulates the HBP andO-GlcNAcmodi-
fication? How does O-GlcNAcylation lead to cardioprotection?
We recently unveiled an intrinsic link between the UPR and
HBP, which provides mechanistic insight into the first question
(Wang et al., 2014). We first observed that Xbp1s is potently
and acutely stimulated by I/R in heart as early as 5 min into the
reperfusion stage. To investigate the relationship between the
UPR and HBP, we focused on the rate-limiting enzyme,
GFAT1. We found that Xbp1s is a direct activator of the gene
coding for GFAT1, based on the presence of an Xbp1s binding
site in its promoter, coupled with luciferase reporter assays
and chromatin immunoprecipitation analysis. Further, we found
that two additional genes within the HBP pathway, as well as
GalE, are also under the control of Xbp1s in vitro and in vivo. Us-
ing a doxycycline-inducible mousemodel, we found that overex-
pression of Xbp1s in cardiomyocytes leads to robust activation
of HBP activity, as documented by increases in UDP-GlcNAc
levels and protein O-GlcNAcylation. Additionally, we found that
the causal link between the UPR and HBP is a generalized phe-
nomenon beyondmyocardial I/R injury. Original work by Zachara
et al. (2004) revealed that various stress conditions in COS-7
cells elicit upregulation of O-GlcNAcylation, which we found to
be associated with induction of Xbp1s and the UPR. We also re-
ported correlation between Xbp1s andO-GlcNAcylation in cardi-
omyocytes exposed to starvation, consistent with prior work
(Zou et al., 2012). Xbp1s overexpression protected heart from
I/R damage in vivo (Wang et al., 2014). In contrast, cardiomyo-
cyte-specific deletion of Xbp1 amplified I/R-induced patholog-
ical cardiac remodeling. GFAT1 and O-GlcNAcylation are
involved, at least partially, in Xbp1s-mediated cardioprotection222 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.ex vivo and in vitro. Thus, our recent report brings together two
large areas of biology and unveils a mechanistic link between
theUPR andHBP, whichmay have broad implications inmultiple
fields (Glembotski, 2014; Vincenz and Hartl, 2014).
Insight into the mechanism of O-GlcNAcylation-mediated car-
dioprotection remains elusive, with several possible explana-
tions suggested by prior studies. Elevations in O-GlcNAc protein
modification protect mitochondria from loss of membrane po-
tential elicited by exposure to hydrogen peroxide (Champattana-
chai et al., 2008; Jones et al., 2008). In addition, increases in
O-GlcNAcylation may suppress expression of the pro-apoptotic
branch of the UPR by suppressing CHOP protein levels (Ngoh
et al., 2009). Recently, it was reported that feeding C. elegans
O-GlcNAc significantly increased life span by inducing auto-
phagy and improving protein folding (Denzel et al., 2014).
O-GlcNAc itself is a unique molecule with a sugar backbone,
an amine group, and an acetyl group. In light of this, it is tempting
to speculate that O-GlcNAc per se may be an ideal source of nu-
trients during energy crises or a storage vehicle when nutrients
are plenty. This way, O-GlcNAc can serve as a metabolic buffer
between feast and famine. Further work is warranted to test this
hypothesis. Collectively, O-GlcNAcylation may protect the cell
from stress-induced demise bymodulating functions of essential
proteins, maintaining integrity of mitochondria, or possibly regu-
lating carbohydrate metabolism.
UPS and Cardiac Hypertrophy
TheUPS is a principal mechanism to degrademisfolded proteins
and facilitate cellular homeostasis (Schlossarek et al., 2014;
Wang and Robbins, 2014). It is a highly regulated, multistep pro-
cess, commencing with ATP-dependent activation of ubiquitin
by activating enzymes, termed E1s. Activated ubiquitin is then
transferred to a conjugating enzyme, termed E2. Ubiquitin li-
gases (E3s), in turn, bind both the E2 and target substrates
and catalyze the ubiquitin modification on lysine(s) of target pro-
teins as well as the subsequent elongation of the poly-ubiquitin
chain. There are two E1s and approximately 40 E2s in the human
genome, but more than 600 E3s, conferring precise selectivity of
protein recognition and degradation.
The presence of attached poly-ubiquitin chains targets a pro-
tein to the 26S proteasome, a protein complex comprising a 20S
catalytic core and one or two 19S regulatory cap particles. Ubiq-
uitinated proteins are recognized, deubiquitinated, unfolded by
the 19S cap, and translocated into the interior of the 20S core
for degradation by proteasomal peptidases. Finally, small pep-
tides are released and quickly hydrolyzed to amino acids. In
some specialized cases, such as processing of the precursor
of the transcription factor NF-kB, degradation can yield a biolog-
ically active protein fragment (Rape and Jentsch, 2002). Beyond
degradation of misfolded proteins, the target turnover of key reg-
ulatory molecules by the UPS has been implicated in cell cycle
control, inflammation, and cell death.
Cardiac hypertrophic growth is exemplified by increased
stress on the myocardium, with consequent turnover and oxida-
tive damage of cardiac proteins. Therefore, the UPS plays an
important role in maintaining cellular function and viability, and
dysfunction of the UPSmay contribute to disease pathogenesis.
Proteasome function, measured as both chymotrypsin-like and
caspase-like activities, is significantly diminished in patients
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Whereas alterations in UPS protein content have not been
reported, post-translational modifications are significantly
increased in hypertrophic human hearts. Failing human hearts
manifest similar reductions in proteasome function. Subsequent
studies showed that reductions in proteasome activity in failing
hearts stem from decreases in ATPase activity and diminished
docking of the 19S regulatory cap to the 20S proteolytic core
(Day et al., 2013). Consistently, failing human hearts are marked
by accumulation of ubiquitinated proteins, cardiac hypertrophy,
and fibrosis (Tsukamoto et al., 2006). Moreover, malfunction of
the UPS precedes cardiac dysfunction in a rodent model of car-
diac hypertrophy (Tsukamoto et al., 2006), and chronic exposure
to a proteasome inhibitor provokes deterioration in cardiac per-
formance in pigs, accompanied by increases in apoptosis and
fibrosis (Herrmann et al., 2013).
Mechanistically, insufficiency of proteasome function may
lead directly to activation of NFAT and consequent hypertro-
phic growth (Tang et al., 2010). However, it has been reported
that pressure overload provokes increases in proteasome
activity in both chronic canine and acute rodent models (Depre
et al., 2006). Consistently, inhibition of proteasome activity
leads to suppression of cardiac hypertrophy when a protea-
some inhibitor is administrated concomitantly with isopro-
terenol (Stansfield et al., 2008). Further, even established
hypertrophy can be regressed by proteasome inhibition. An
explanation for this apparent discrepancy has not emerged,
although these studies involve distinct models, different stages
of hypertrophy and heart failure, and different degrees of pro-
teasome inhibition.
UPS and Myocardial Infarction
Reperfusion following myocardial infarction is associated with
profound remodeling of cellular architecture and machinery.
In this setting, the UPS is critically involved. Inflammation is
one of the most important contributors to I/R injury. Sudden in-
creases in ROS elicit protein misfolding and damage. Activation
of NF-kB, a master regulator of inflammatory responses, relies
on proteolytic degradation of IkBa, the inhibitor of IKK and NF-
kB activity. Pharmacological inhibition of global UPS activity
with a 20S proteasome inhibitor suppresses NF-kB activation
and leads to strong cardioprotective effects in pigs (Pye
et al., 2003). Consistently, administration of the same inhibitor
before myocardial infarction, or even during reperfusion, elicits
significant protection against I/R damage in mice (Stansfield
et al., 2007). In both cases, suppression of NF-kB activity is
involved.
Manipulation of UPS activity specifically in cardiomyocytes,
however, provokes different results. Three enzymatic activities
of the UPS are reportedly suppressed by I/R in mice (Tian
et al., 2012). Working with a model of cardiomyocyte-restricted
overexpression of a peptidase-disabled mutant of the 20S com-
plex b5 subunit, thereby inhibiting endogenous chymotrypsin-
like activity in 26S proteasome, Tian et al. (2012) concluded
that inhibition of the UPS in cardiomyocytes leads to deteriora-
tion of the cardiac response to I/R and increases in apoptosis.
In contrast, overexpression of the PA28a (an alternative regula-
tory subunit independent of ubiquitin chain targeting) in cardio-
myocytes to enhance proteasomal protease activity protectsmouse hearts from I/R damage and prevents accumulation of
misfolded proteins (Li et al., 2011). This finding may be eluci-
dated by a recent report that PA28a can play a special role in
the removal of oxidatively damaged proteins (Hernebring et al.,
2013). Thus, modulation of the UPS within cardiomyocytes
versus non-cardiomyocytes results in distinct phenotypes, call-
ing for caution when addressing the function of UPS in cardiac
I/R injury.
Conclusion and Perspectives
Even as we have witnessed robust advances in our understand-
ing and treatment of CVD, the disease continues to evolve and
expand. As a consequence, effective treatments are still lacking,
and CVD remains the leading cause of morbidity and mortality
worldwide. Due to its minimal capacity for replication, the cardi-
omyocyte is uniquely reliant on mechanisms of protein quality
control. Owing to its incessant requirement of high levels of
energy, metabolic processes in the myocyte are similarly para-
mount. At some level, then, it is not surprising that these two pro-
cesses—protein quality control and cellular metabolism—are
intimately linked.
Autophagy, the UPR, and the UPS are the principal mecha-
nisms to degrade misfolded proteins and defective organelles,
serving to maintain a functional cellular environment. Malfunc-
tion and dysregulation of any of these processes contributes to
disease, such as cardiac hypertrophy, myocardial infarction,
and heart failure. Further, each of thesemechanisms is intimately
linked to the interlacing cascades of metabolism. Precise
dissection of the complex interplay between protein quality con-
trol systems and their metabolic context and consequences is
mandatory. It is our expectation that coordinated understanding
of this fascinating biology will propel us toward novel therapeutic
targets with clinical relevance.
ACKNOWLEDGMENTS
We thank members of the Hill lab for constructive comments.
This work was supported by grants from the NIH (HL-120732; HL-100401),
AHA (14SFRN20740000), CPRIT (RP110486P3), and the Leducq Foundation
(11CVD04). Z.V.W. was supported by a Scientist Development Grant from
the American Heart Association (14SDG18440002). We declare no conflicts
of interest.
REFERENCES
Allard, M.F., Scho¨nekess, B.O., Henning, S.L., English, D.R., and Lopaschuk,
G.D. (1994). Contribution of oxidative metabolism and glycolysis to ATP pro-
duction in hypertrophied hearts. Am. J. Physiol. 267, H742–H750.
Antos, C.L., McKinsey, T.A., Dreitz, M., Hollingsworth, L.M., Zhang, C.L.,
Schreiber, K., Rindt, H., Gorczynski, R.J., and Olson, E.N. (2003). Dose-
dependent blockade to cardiomyocyte hypertrophy by histone deacetylase in-
hibitors. J. Biol. Chem. 278, 28930–28937.
Back, S.H., and Kaufman, R.J. (2012). Endoplasmic reticulum stress and type
2 diabetes. Annu. Rev. Biochem. 81, 767–793.
Belmont, P.J., Tadimalla, A., Chen, W.J., Martindale, J.J., Thuerauf, D.J., Mar-
cinko, M., Gude, N., Sussman, M.A., and Glembotski, C.C. (2008). Coordina-
tion of growth and endoplasmic reticulum stress signaling by regulator of
calcineurin 1 (RCAN1), a novel ATF6-inducible gene. J. Biol. Chem. 283,
14012–14021.
Bergmann, O., Bhardwaj, R.D., Bernard, S., Zdunek, S., Barnabe´-Heider, F.,
Walsh, S., Zupicich, J., Alkass, K., Buchholz, B.A., Druid, H., et al. (2009).
Evidence for cardiomyocyte renewal in humans. Science 324, 98–102.Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 223
Cell Metabolism
PerspectiveBhuiyan, M.S., Pattison, J.S., Osinska, H., James, J., Gulick, J., McLendon,
P.M., Hill, J.A., Sadoshima, J., and Robbins, J. (2013). Enhanced autophagy
ameliorates cardiac proteinopathy. J. Clin. Invest. 123, 5284–5297.
Blobel, G. (2000). Protein targeting. Biosci. Rep. 20, 303–344.
Bond,M.R., and Hanover, J.A. (2013). O-GlcNAc cycling: a link betweenmeta-
bolism and chronic disease. Annu. Rev. Nutr. 33, 205–229.
Burchfield, J.S., Xie, M., and Hill, J.A. (2013). Pathological ventricular remod-
eling: mechanisms: part 1 of 2. Circulation 128, 388–400.
Cao, D.J., Wang, Z.V., Battiprolu, P.K., Jiang, N., Morales, C.R., Kong, Y.,
Rothermel, B.A., Gillette, T.G., and Hill, J.A. (2011). Histone deacetylase
(HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy.
Proc. Natl. Acad. Sci. USA 108, 4123–4128.
Chaanine, A.H., Jeong, D., Liang, L., Chemaly, E.R., Fish, K., Gordon, R.E., and
Hajjar, R.J. (2012). JNK modulates FOXO3a for the expression of the mito-
chondrial death and mitophagy marker BNIP3 in pathological hypertrophy
and in heart failure. Cell Death Dis. 3, 265.
Champattanachai, V., Marchase, R.B., and Chatham, J.C. (2008). Glucos-
amine protects neonatal cardiomyocytes from ischemia-reperfusion injury
via increased protein O-GlcNAc and increased mitochondrial Bcl-2. Am. J.
Physiol. Cell Physiol. 294, C1509–C1520.
Dai, D.F., Johnson, S.C., Villarin, J.J., Chin, M.T., Nieves-Cintro´n, M., Chen, T.,
Marcinek, D.J., Dorn, G.W., 2nd, Kang, Y.J., Prolla, T.A., et al. (2011). Mito-
chondrial oxidative stress mediates angiotensin II-induced cardiac hypertro-
phy and Galphaq overexpression-induced heart failure. Circ. Res. 108,
837–846.
Day, S.M., Divald, A., Wang, P., Davis, F., Bartolone, S., Jones, R., and Powell,
S.R. (2013). Impaired assembly and post-translational regulation of 26S pro-
teasome in human end-stage heart failure. Circ Heart Fail 6, 544–549.
Decker, R.S., and Wildenthal, K. (1980). Lysosomal alterations in hypoxic and
reoxygenated hearts. I. Ultrastructural and cytochemical changes. Am. J.
Pathol. 98, 425–444.
Deng, Y., Wang, Z.V., Tao, C., Gao, N., Holland, W.L., Ferdous, A., Repa, J.J.,
Liang, G., Ye, J., Lehrman, M.A., et al. (2013). The Xbp1s/GalE axis links ER
stress to postprandial hepatic metabolism. J. Clin. Invest. 123, 455–468.
Denzel, M.S., Storm, N.J., Gutschmidt, A., Baddi, R., Hinze, Y., Jarosch, E.,
Sommer, T., Hoppe, T., and Antebi, A. (2014). Hexosamine pathway metabo-
lites enhance protein quality control and prolong life. Cell 156, 1167–1178.
Depre, C., Wang, Q., Yan, L., Hedhli, N., Peter, P., Chen, L., Hong, C., Hittinger,
L., Ghaleh, B., Sadoshima, J., et al. (2006). Activation of the cardiac protea-
some during pressure overload promotes ventricular hypertrophy. Circulation
114, 1821–1828.
Doroudgar, S., andGlembotski, C.C. (2013). New concepts of endoplasmic re-
ticulum function in the heart: programmed to conserve. J. Mol. Cell. Cardiol.
55, 85–91.
Doroudgar, S., Thuerauf, D.J., Marcinko,M.C., Belmont, P.J., andGlembotski,
C.C. (2009). Ischemia activates the ATF6 branch of the endoplasmic reticulum
stress response. J. Biol. Chem. 284, 29735–29745.
Feng, Y., He, D., Yao, Z., and Klionsky, D.J. (2014). The machinery of macro-
autophagy. Cell Res. 24, 24–41.
Frey, N., Katus, H.A., Olson, E.N., and Hill, J.A. (2004). Hypertrophy of the
heart: a new therapeutic target? Circulation 109, 1580–1589.
Fu, H.Y., Okada, K., Liao, Y., Tsukamoto, O., Isomura, T., Asai, M., Sawada, T.,
Okuda, K., Asano, Y., Sanada, S., et al. (2010). Ablation of C/EBP homologous
protein attenuates endoplasmic reticulum-mediated apoptosis and cardiac
dysfunction induced by pressure overload. Circulation 122, 361–369.
Fu, S., Watkins, S.M., and Hotamisligil, G.S. (2012). The role of endoplasmic
reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab. 15,
623–634.
Glembotski, C.C. (2014). Finding themissing link between the unfolded protein
response and O-GlcNAcylation in the heart. Circ. Res. 115, 546–548.
Hamacher-Brady, A., Brady, N.R., and Gottlieb, R.A. (2006). Enhancing mac-
roautophagy protects against ischemia/reperfusion injury in cardiac myo-
cytes. J. Biol. Chem. 281, 29776–29787.224 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.Hariharan, N., Maejima, Y., Nakae, J., Paik, J., Depinho, R.A., and Sadoshima,
J. (2010). Deacetylation of FoxO by Sirt1 Plays an Essential Role in Mediating
Starvation-Induced Autophagy in Cardiac Myocytes. Circ. Res. 107, 1470–
1482.
Hart, G.W., Slawson, C., Ramirez-Correa, G., and Lagerlof, O. (2011). Cross
talk between O-GlcNAcylation and phosphorylation: roles in signaling, tran-
scription, and chronic disease. Annu. Rev. Biochem. 80, 825–858.
Hausenloy, D.J., and Yellon, D.M. (2013). Myocardial ischemia-reperfusion
injury: a neglected therapeutic target. J. Clin. Invest. 123, 92–100.
Heineke, J., and Molkentin, J.D. (2006). Regulation of cardiac hypertrophy by
intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7, 589–600.
Hernebring, M., Fredriksson, A., Liljevald, M., Cvijovic, M., Norrman, K., Wise-
man, J., Semb, H., and Nystrom, T. (2013). Removal of damaged proteins
during ES cell fate specification requires the proteasome activator PA28.
Sci. Rep. 3, http://dx.doi.org/10.1038/srep01381.
Herrmann, J., Wohlert, C., Saguner, A.M., Flores, A., Nesbitt, L.L., Chade, A.,
Lerman, L.O., and Lerman, A. (2013). Primary proteasome inhibition results in
cardiac dysfunction. Eur. J. Heart Fail. 15, 614–623.
Hetz, C., and Mollereau, B. (2014). Disturbance of endoplasmic reticulum pro-
teostasis in neurodegenerative diseases. Nat. Rev. Neurosci. 15, 233–249.
Hetz, C., Chevet, E., and Harding, H.P. (2013). Targeting the unfolded protein
response in disease. Nat. Rev. Drug Discov. 12, 703–719.
Hill, J.A., andOlson, E.N. (2008). Cardiac plasticity. N. Engl. J. Med. 358, 1370–
1380.
Hu, Y., Sun, Q., Li, Z., Chen, J., Shen, C., Song, Y., and Zhong, Q. (2014). High
basal level of autophagy in high-altitude residents attenuates myocardial
ischemia-reperfusion injury. J. Thorac. Cardiovasc. Surg. 148, 1674–1680.
Jones, S.P., Zachara, N.E., Ngoh, G.A., Hill, B.G., Teshima, Y., Bhatnagar, A.,
Hart, G.W., and Marba´n, E. (2008). Cardioprotection by N-acetylglucosamine
linkage to cellular proteins. Circulation 117, 1172–1182.
Kanamori, H., Takemura, G., Maruyama, R., Goto, K., Tsujimoto, A., Ogino, A.,
Li, L., Kawamura, I., Takeyama, T., Kawaguchi, T., et al. (2009). Functional sig-
nificance and morphological characterization of starvation-induced auto-
phagy in the adult heart. Am. J. Pathol. 174, 1705–1714.
Kato, T., Niizuma, S., Inuzuka, Y., Kawashima, T., Okuda, J., Tamaki, Y., Iwa-
naga, Y., Narazaki, M., Matsuda, T., Soga, T., et al. (2010). Analysis of meta-
bolic remodeling in compensated left ventricular hypertrophy and heart failure.
Circ Heart Fail 3, 420–430.
Kenific, C.M., and Debnath, J. (2015). Cellular and metabolic functions for
autophagy in cancer cells. Trends Cell Biol. 25, 37–45.
Kong, Y., Tannous, P., Lu, G., Berenji, K., Rothermel, B.A., Olson, E.N., and
Hill, J.A. (2006). Suppression of class I and II histone deacetylases blunts pres-
sure-overload cardiac hypertrophy. Circulation 113, 2579–2588.
Koumenis, C., Naczki, C., Koritzinsky, M., Rastani, S., Diehl, A., Sonenberg, N.,
Koromilas, A., and Wouters, B.G. (2002). Regulation of protein synthesis by
hypoxia via activation of the endoplasmic reticulum kinase PERK and phos-
phorylation of the translation initiation factor eIF2alpha. Mol. Cell. Biol. 22,
7405–7416.
Kuma, A., Hatano, M., Matsui, M., Yamamoto, A., Nakaya, H., Yoshimori, T.,
Ohsumi, Y., Tokuhisa, T., andMizushima, N. (2004). The role of autophagy dur-
ing the early neonatal starvation period. Nature 432, 1032–1036.
Li, J., Horak, K.M., Su, H., Sanbe, A., Robbins, J., and Wang, X. (2011).
Enhancement of proteasomal function protects against cardiac proteinopathy
and ischemia/reperfusion injury in mice. J. Clin. Invest. 121, 3689–3700.
Lin, J.H., Li, H., Yasumura, D., Cohen, H.R., Zhang, C., Panning, B., Shokat,
K.M., Lavail, M.M., andWalter, P. (2007). IRE1 signaling affects cell fate during
the unfolded protein response. Science 318, 944–949.
Liu, J., Marchase, R.B., and Chatham, J.C. (2007). Increased O-GlcNAc levels
during reperfusion lead to improved functional recovery and reduced calpain
proteolysis. Am. J. Physiol. Heart Circ. Physiol. 293, H1391–H1399.
Locasale, J.W., and Cantley, L.C. (2011). Metabolic flux and the regulation of
mammalian cell growth. Cell Metab. 14, 443–451.
Cell Metabolism
PerspectiveLock, R., Roy, S., Kenific, C.M., Su, J.S., Salas, E., Ronen, S.M., and Debnath,
J. (2011). Autophagy facilitates glycolysis during Ras-mediated oncogenic
transformation. Mol. Biol. Cell 22, 165–178.
Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S., and Stanley, W.C.
(2010). Myocardial fatty acid metabolism in health and disease. Physiol. Rev.
90, 207–258.
Lu, P.D., Jousse, C., Marciniak, S.J., Zhang, Y., Novoa, I., Scheuner, D., Kauf-
man, R.J., Ron, D., and Harding, H.P. (2004). Cytoprotection by pre-emptive
conditional phosphorylation of translation initiation factor 2. EMBO J. 23,
169–179.
Ma, X., Liu, H., Foyil, S.R., Godar, R.J., Weinheimer, C.J., Hill, J.A., and Diwan,
A. (2012). Impaired autophagosome clearance contributes to cardiomyocyte
death in ischemia/reperfusion injury. Circulation 125, 3170–3181.
Marsh, S.A., Collins, H.E., and Chatham, J.C. (2014). Protein O-GlcNAcylation
and Cardiovascular (Patho)physiology. J. Biol. Chem. 289, 34449–34456.
Martindale, J.J., Fernandez, R., Thuerauf, D., Whittaker, R., Gude, N., Suss-
man, M.A., and Glembotski, C.C. (2006). Endoplasmic reticulum stress gene
induction and protection from ischemia/reperfusion injury in the hearts of
transgenic mice with a tamoxifen-regulated form of ATF6. Circ. Res. 98,
1186–1193.
Maruyama, R., Goto, K., Takemura, G., Ono, K., Nagao, K., Horie, T., Tsuji-
moto, A., Kanamori, H., Miyata, S., Ushikoshi, H., et al. (2008). Morphological
and biochemical characterization of basal and starvation-induced autophagy
in isolated adult rat cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 295,
H1599–H1607.
Mathers, C.D., and Loncar, D. (2006). Projections of global mortality and
burden of disease from 2002 to 2030. PLoS Med. 3, e442.
Matsui, Y., Takagi, H., Qu, X., Abdellatif, M., Sakoda, H., Asano, T., Levine, B.,
and Sadoshima, J. (2007). Distinct roles of autophagy in the heart during
ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin
1 in mediating autophagy. Circ. Res. 100, 914–922.
Mearini, G., Schlossarek, S., Willis, M.S., and Carrier, L. (2008). The ubiquitin-
proteasome system in cardiac dysfunction. Biochim. Biophys. Acta 1782,
749–763.
Miyazaki, Y., Kaikita, K., Endo, M., Horio, E., Miura, M., Tsujita, K., Hokimoto,
S., Yamamuro, M., Iwawaki, T., Gotoh, T., et al. (2011). C/EBP homologous
protein deficiency attenuates myocardial reperfusion injury by inhibiting
myocardial apoptosis and inflammation. Arterioscler. Thromb. Vasc. Biol.
31, 1124–1132.
Mizushima, N., Levine, B., Cuervo, A.M., and Klionsky, D.J. (2008). Autophagy
fights disease through cellular self-digestion. Nature 451, 1069–1075.
Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman,
M., de Ferranti, S., Despres, J., Fullerton, H.J., Howard, V.J., et al. (2014).
Heart Disease and Stroke Statistics-2015 Update: A Report From the Amer-
ican Heart Association. Circulation. Published online December 17, 2014.
http://dx.doi.org/10.1161/CIR.0000000000000152.
Murphy, E., and Steenbergen, C. (2008). Mechanisms underlying acute pro-
tection from cardiac ischemia-reperfusion injury. Physiol. Rev. 88, 581–609.
Nabel, E.G., and Braunwald, E. (2012). A tale of coronary artery disease and
myocardial infarction. N. Engl. J. Med. 366, 54–63.
Nakai, A., Yamaguchi, O., Takeda, T., Higuchi, Y., Hikoso, S., Taniike, M.,
Omiya, S., Mizote, I., Matsumura, Y., Asahi, M., et al. (2007). The role of auto-
phagy in cardiomyocytes in the basal state and in response to hemodynamic
stress. Nat. Med. 13, 619–624.
Ngoh, G.A., Hamid, T., Prabhu, S.D., and Jones, S.P. (2009). O-GlcNAc
signaling attenuates ER stress-induced cardiomyocyte death. Am. J. Physiol.
Heart Circ. Physiol. 297, H1711–H1719.
Nishino, I., Fu, J., Tanji, K., Yamada, T., Shimojo, S., Koori, T., Mora, M., Riggs,
J.E., Oh, S.J., Koga, Y., et al. (2000). Primary LAMP-2 deficiency causes X-
linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406,
906–910.
Okada, K., Minamino, T., Tsukamoto, Y., Liao, Y., Tsukamoto, O., Takashima,
S., Hirata, A., Fujita, M., Nagamachi, Y., Nakatani, T., et al. (2004). Prolonged
endoplasmic reticulum stress in hypertrophic and failing heart after aorticconstriction: possible contribution of endoplasmic reticulum stress to cardiac
myocyte apoptosis. Circulation 110, 705–712.
Pattison, J.S., Osinska, H., and Robbins, J. (2011). Atg7 induces basal auto-
phagy and rescues autophagic deficiency in CryABR120G cardiomyocytes.
Circ. Res. 109, 151–160.
Petrovski, G., Das, S., Juhasz, B., Kertesz, A., Tosaki, A., and Das, D.K. (2011).
Cardioprotection by endoplasmic reticulum stress-induced autophagy. Anti-
oxid. Redox Signal. 14, 2191–2200.
Pfeifer, U., Fo¨hr, J., Wilhelm, W., and Da¨mmrich, J. (1987). Short-term inhibi-
tion of cardiac cellular autophagy by isoproterenol. J. Mol. Cell. Cardiol. 19,
1179–1184.
Porrello, E.R., D’Amore, A., Curl, C.L., Allen, A.M., Harrap, S.B., Thomas,
W.G., and Delbridge, L.M. (2009). Angiotensin II type 2 receptor antagonizes
angiotensin II type 1 receptor-mediated cardiomyocyte autophagy. Hyperten-
sion 53, 1032–1040.
Predmore, J.M., Wang, P., Davis, F., Bartolone, S., Westfall, M.V., Dyke, D.B.,
Pagani, F., Powell, S.R., and Day, S.M. (2010). Ubiquitin proteasome dysfunc-
tion in human hypertrophic and dilated cardiomyopathies. Circulation 121,
997–1004.
Pye, J., Ardeshirpour, F., McCain, A., Bellinger, D.A., Merricks, E., Adams, J.,
Elliott, P.J., Pien, C., Fischer, T.H., Baldwin, A.S., Jr., and Nichols, T.C. (2003).
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfu-
sion and reduces reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 284,
H919–H926.
Rabinowitz, J.D., and White, E. (2010). Autophagy and metabolism. Science
330, 1344–1348.
Rajasekaran, N.S., Connell, P., Christians, E.S., Yan, L.J., Taylor, R.P., Orosz,
A., Zhang, X.Q., Stevenson, T.J., Peshock, R.M., Leopold, J.A., et al. (2007).
Human alpha B-crystallin mutation causes oxido-reductive stress and protein
aggregation cardiomyopathy in mice. Cell 130, 427–439.
Rape, M., and Jentsch, S. (2002). Taking a bite: proteasomal protein process-
ing. Nat. Cell Biol. 4, E113–E116.
Riehle, C., Wende, A.R., Sena, S., Pires, K.M., Pereira, R.O., Zhu, Y., Bugger,
H., Frank, D., Bevins, J., Chen, D., et al. (2013). Insulin receptor substrate
signaling suppresses neonatal autophagy in the heart. J. Clin. Invest. 123,
5319–5333.
Rothermel, B.A., and Hill, J.A. (2008). Autophagy in load-induced heart dis-
ease. Circ. Res. 103, 1363–1369.
Sala-Mercado, J.A., Wider, J., Undyala, V.V., Jahania, S., Yoo, W., Mentzer,
R.M., Jr., Gottlieb, R.A., and Przyklenk, K. (2010). Profound cardioprotection
with chloramphenicol succinate in the swinemodel of myocardial ischemia-re-
perfusion injury. Circulation 122 (Suppl ), S179–S184.
Sanbe, A., Osinska, H., Saffitz, J.E., Glabe, C.G., Kayed, R., Maloyan, A., and
Robbins, J. (2004). Desmin-related cardiomyopathy in transgenic mice: a car-
diac amyloidosis. Proc. Natl. Acad. Sci. USA 101, 10132–10136.
Sawada, T., Minamino, T., Fu, H.Y., Asai, M., Okuda, K., Isomura, T., Yama-
zaki, S., Asano, Y., Okada, K., Tsukamoto, O., et al. (2010). X-box binding pro-
tein 1 regulates brain natriuretic peptide through a novel AP1/CRE-like element
in cardiomyocytes. J. Mol. Cell. Cardiol. 48, 1280–1289.
Schlossarek, S., Frey, N., and Carrier, L. (2014). Ubiquitin-proteasome system
and hereditary cardiomyopathies. J. Mol. Cell. Cardiol. 71, 25–31.
Schro¨der, M., and Kaufman, R.J. (2005). The mammalian unfolded protein
response. Annu. Rev. Biochem. 74, 739–789.
Sengupta, A., Molkentin, J.D., Paik, J.H., DePinho, R.A., and Yutzey, K.E.
(2011). FoxO transcription factors promote cardiomyocyte survival upon in-
duction of oxidative stress. J. Biol. Chem. 286, 7468–7478.
Severino, A., Campioni, M., Straino, S., Salloum, F.N., Schmidt, N., Herbrand,
U., Frede, S., Toietta, G., Di Rocco, G., Bussani, R., et al. (2007). Identification
of protein disulfide isomerase as a cardiomyocyte survival factor in ischemic
cardiomyopathy. J. Am. Coll. Cardiol. 50, 1029–1037.
Shimizu, I., Minamino, T., Toko, H., Okada, S., Ikeda, H., Yasuda, N., Tateno,
K., Moriya, J., Yokoyama, M., Nojima, A., et al. (2010). Excessive cardiac insu-
lin signaling exacerbates systolic dysfunction induced by pressure overload in
rodents. J. Clin. Invest. 120, 1506–1514.Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 225
Cell Metabolism
PerspectiveSorokina, N., O’Donnell, J.M., McKinney, R.D., Pound, K.M., Woldegiorgis, G.,
LaNoue, K.F., Ballal, K., Taegtmeyer, H., Buttrick, P.M., and Lewandowski,
E.D. (2007). Recruitment of compensatory pathways to sustain oxidative flux
with reduced carnitine palmitoyltransferase I activity characterizes inefficiency
in energy metabolism in hypertrophied hearts. Circulation 115, 2033–2041.
Stanley, W.C., Recchia, F.A., and Lopaschuk, G.D. (2005). Myocardial sub-
strate metabolism in the normal and failing heart. Physiol. Rev. 85, 1093–1129.
Stansfield, W.E., Moss, N.C., Willis, M.S., Tang, R., and Selzman, C.H. (2007).
Proteasome inhibition attenuates infarct size and preserves cardiac function in
a murine model of myocardial ischemia-reperfusion injury. Ann. Thorac. Surg.
84, 120–125.
Stansfield, W.E., Tang, R.H., Moss, N.C., Baldwin, A.S., Willis, M.S., and Selz-
man, C.H. (2008). Proteasome inhibition promotes regression of left ventricular
hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 294, H645–H650.
Sun, X., Momen, A., Wu, J., Noyan, H., Li, R., von Harsdorf, R., and Husain, M.
(2014). p27 protein protects metabolically stressed cardiomyocytes from
apoptosis by promoting autophagy. J. Biol. Chem. 289, 16924–16935.
Tabas, I., and Ron, D. (2011). Integrating the mechanisms of apoptosis
induced by endoplasmic reticulum stress. Nat. Cell Biol. 13, 184–190.
Tanaka, Y., Guhde, G., Suter, A., Eskelinen, E.L., Hartmann, D., Lu¨llmann-
Rauch, R., Janssen, P.M., Blanz, J., von Figura, K., and Saftig, P. (2000). Accu-
mulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient
mice. Nature 406, 902–906.
Tang, M., Li, J., Huang, W., Su, H., Liang, Q., Tian, Z., Horak, K.M., Molkentin,
J.D., and Wang, X. (2010). Proteasome functional insufficiency activates the
calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive re-
modelling of stressed mouse hearts. Cardiovasc. Res. 88, 424–433.
Tannous, P., Zhu, H., Johnstone, J.L., Shelton, J.M., Rajasekaran, N.S.,
Benjamin, I.J., Nguyen, L., Gerard, R.D., Levine, B., Rothermel, B.A., and
Hill, J.A. (2008). Autophagy is an adaptive response in desmin-related cardio-
myopathy. Proc. Natl. Acad. Sci. USA 105, 9745–9750.
Tarone, G., and Brancaccio, M. (2014). Keep your heart in shape: molecular
chaperone networks for treating heart disease. Cardiovasc. Res. 102,
346–361.
Thuerauf, D.J., Marcinko, M., Gude, N., Rubio, M., Sussman, M.A., and Glem-
botski, C.C. (2006). Activation of the unfolded protein response in infarcted
mouse heart and hypoxic cultured cardiac myocytes. Circ. Res. 99, 275–282.
Tian, Z., Zheng, H., Li, J., Li, Y., Su, H., and Wang, X. (2012). Genetically
induced moderate inhibition of the proteasome in cardiomyocytes exacer-
batesmyocardial ischemia-reperfusion injury in mice. Circ. Res. 111, 532–542.
Tsukamoto, O., Minamino, T., Okada, K., Shintani, Y., Takashima, S., Kato, H.,
Liao, Y., Okazaki, H., Asai, M., Hirata, A., et al. (2006). Depression of protea-
some activities during the progression of cardiac dysfunction in pressure-
overloaded heart of mice. Biochem. Biophys. Res. Commun. 340, 1125–1133.
Turer, A.T., and Hill, J.A. (2010). Pathogenesis of myocardial ischemia-reper-
fusion injury and rationale for therapy. Am. J. Cardiol. 106, 360–368.
Valentim, L., Laurence, K.M., Townsend, P.A., Carroll, C.J., Soond, S., Scara-
belli, T.M., Knight, R.A., Latchman, D.S., and Stephanou, A. (2006). Urocortin
inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed
to ischaemia/reperfusion injury. J. Mol. Cell. Cardiol. 40, 846–852.
Vincenz, L., and Hartl, F.U. (2014). Sugarcoating ER Stress. Cell 156, 1125–
1127.
Walter, P., and Ron, D. (2011). The unfolded protein response: from stress
pathway to homeostatic regulation. Science 334, 1081–1086.
Wang, M., and Kaufman, R.J. (2014). The impact of the endoplasmic reticulum
protein-folding environment on cancer development. Nat. Rev. Cancer 14,
581–597.226 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.Wang, X., and Robbins, J. (2014). Proteasomal and lysosomal protein degra-
dation and heart disease. J. Mol. Cell. Cardiol. 71, 16–24.
Wang, Z.V., Deng, Y., Gao, N., Pedrozo, Z., Li, D.L., Morales, C.R., Criollo, A.,
Luo, X., Tan, W., Jiang, N., et al. (2014). Spliced X-box binding protein 1 cou-
ples the unfolded protein response to hexosamine biosynthetic pathway. Cell
156, 1179–1192.
Watson, L.J., Facundo, H.T., Ngoh, G.A., Ameen, M., Brainard, R.E., Lemma,
K.M., Long, B.W., Prabhu, S.D., Xuan, Y.T., and Jones, S.P. (2010). O-linked
b-N-acetylglucosamine transferase is indispensable in the failing heart. Proc.
Natl. Acad. Sci. USA 107, 17797–17802.
Wei, H., Wei, S., Gan, B., Peng, X., Zou, W., and Guan, J.L. (2011). Suppres-
sion of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes
Dev. 25, 1510–1527.
Willis, M.S., and Patterson, C. (2010). Hold me tight: Role of the heat shock
protein family of chaperones in cardiac disease. Circulation 122, 1740–1751.
Willis, M.S., and Patterson, C. (2013). Proteotoxicity and cardiac dysfunction.
N. Engl. J. Med. 368, 1755.
Xie, M., Kong, Y., Tan, W., May, H., Battiprolu, P.K., Pedrozo, Z., Wang, Z.V.,
Morales, C., Luo, X., Cho, G., et al. (2014). Histone deacetylase inhibition
blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Cir-
culation 129, 1139–1151.
Xin, W., Lu, X., Li, X., Niu, K., and Cai, J. (2011). Attenuation of endoplasmic
reticulum stress-related myocardial apoptosis by SERCA2a gene delivery in
ischemic heart disease. Mol. Med. 17, 201–210.
Xu, X., Pacheco, B.D., Leng, L., Bucala, R., and Ren, J. (2013). Macrophage
migration inhibitory factor plays a permissive role in the maintenance of car-
diac contractile function under starvation through regulation of autophagy.
Cardiovasc. Res. 99, 412–421.
Yan, L., Vatner, D.E., Kim, S.J., Ge, H., Masurekar, M., Massover, W.H., Yang,
G., Matsui, Y., Sadoshima, J., and Vatner, S.F. (2005). Autophagy in chroni-
cally ischemic myocardium. Proc. Natl. Acad. Sci. USA 102, 13807–13812.
Ye, J., Rawson, R.B., Komuro, R., Chen, X., Dave´, U.P., Prywes, R., Brown,
M.S., and Goldstein, J.L. (2000). ER stress induces cleavage of membrane-
bound ATF6 by the same proteases that process SREBPs. Mol. Cell 6,
1355–1364.
Young, M.E., Yan, J., Razeghi, P., Cooksey, R.C., Guthrie, P.H., Stepkowski,
S.M., McClain, D.A., Tian, R., and Taegtmeyer, H. (2007). Proposed regulation
of gene expression by glucose in rodent heart. Gene Regul Syst Bio 1,
251–262.
Zachara, N.E. (2012). The roles of O-linked b-N-acetylglucosamine in cardio-
vascular physiology and disease. Am. J. Physiol. Heart Circ. Physiol. 302,
H1905–H1918.
Zachara, N.E., O’Donnell, N., Cheung, W.D., Mercer, J.J., Marth, J.D., and
Hart, G.W. (2004). Dynamic O-GlcNAc modification of nucleocytoplasmic pro-
teins in response to stress. A survival response of mammalian cells. J. Biol.
Chem. 279, 30133–30142.
Zhang, H., Bosch-Marce, M., Shimoda, L.A., Tan, Y.S., Baek, J.H., Wesley,
J.B., Gonzalez, F.J., and Semenza, G.L. (2008). Mitochondrial autophagy is
an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem.
283, 10892–10903.
Zhu, H., Tannous, P., Johnstone, J.L., Kong, Y., Shelton, J.M., Richardson,
J.A., Le, V., Levine, B., Rothermel, B.A., and Hill, J.A. (2007). Cardiac auto-
phagy is a maladaptive response to hemodynamic stress. J. Clin. Invest.
117, 1782–1793.
Zou, L., Zhu-Mauldin, X., Marchase, R.B., Paterson, A.J., Liu, J., Yang, Q., and
Chatham, J.C. (2012). Glucose deprivation-induced increase in protein O-
GlcNAcylation in cardiomyocytes is calcium-dependent. J. Biol. Chem. 287,
34419–34431.
